Effectiveness of two coronavirus disease 2019 (COVID-19) vaccines (viral vector and inactivated viral vaccine) against severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection in a cohort of healthcare workers
Alexandre R. Marra,João Luiz Miraglia,Daniel Tavares Malheiros,Yang Guozhang,Vanessa Damazio Teich,Elivane da Silva Victor,João Renato Rebello Pinho,Adriana Cypriano,Laura Wanderly Vieira,Miria Polonio,Rafael Herrera Ornelas,Solange Miranda de Oliveira,Audrey Rie Ogawa Shibata,Guilherme de Paula Pinto Schettino,Ketti Gleyzer de Oliveira,Rúbia Anita Ferraz Santana,Fernanda de Mello Malta,Deyvid Amgarten,Ana Laura Boechat,Noelly Maria Zimpel Trecenti,Takaaki Kobayashi,Jorge L. Salinas,Michael B. Edmond,Luiz Vicente Rizzo,Flavio Araujo Borges Junior
DOI: https://doi.org/10.1017/ice.2022.50
2022-03-30
Infection Control and Hospital Epidemiology
Abstract:Abstract Objective: We investigated real-world vaccine effectiveness for Oxford-AstraZeneca (ChAdOx1) and CoronaVac against laboratory-confirmed severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection among healthcare workers (HCWs). Methods: We conducted a retrospective cohort study among HCWs (aged ≥18 years) working in a private healthcare system in Brazil between January 1, 2021 and August 3, 2021, to assess vaccine effectiveness. We calculated vaccine effectiveness as 1 − rate ratio (RR), with RR determined by adjusting Poisson models with the occurrence of SARS-CoV-2 infection as the outcome and the vaccination status as the main variable. We used the logarithmic link function and simple models adjusting for sex, age, and job types. Results: In total, 13,813 HCWs met the inclusion criteria for this analysis. Among them, 6,385 (46.2%) received the CoronaVac vaccine, 5,916 (42.8%) received the ChAdOx1 vaccine, and 1,512 (11.0%) were not vaccinated. Overall, COVID-19 occurred in 6% of unvaccinated HCWs, 3% of HCWs who received 2 doses of CoronaVac vaccine, and 0.7% of HCWs who received 2 doses of ChAdOx1 vaccine ( P < .001). In the adjusted analyses, the estimated vaccine effectiveness rates were 51.3% for CoronaVac, and 88.1% for ChAdOx1 vaccine. Both vaccines reduced the number of hospitalizations, the length of hospital stay, and the need for mechanical ventilation. In addition, 19 SARS-CoV-2 samples from 19 HCWs were screened for mutations of interest. Of 19 samples, 18 were the γ (gamma) variant. Conclusions: Although both COVID-19 vaccines (viral vector and inactivated virus) can significantly prevent COVID-19 among HCWs, CoronaVac was much less effective. The COVID-19 vaccines were also effective against the dominant γ variant.
infectious diseases,public, environmental & occupational health